Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554279 · ClinicalTrials.gov registry record · Phase 4
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
A Phase 4 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 620
- Enrollment target
NCT02554279: Completed Phase 4 study, sponsored by Ferring Pharmaceuticals.
NCT02554279 is a Phase 4 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 620 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554279, a Phase 4 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 620 participants
- Enrollment target
Study Summary
The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation (COS) following GnRH treatment.
Primary Outcome
Defined as the percentage of participants with the presence of at least 1 intrauterine pregnancy with a detectable fetal heartbeat at 10-11 weeks of gestation.
Interventions
- DRUG recombinant FSH
- DRUG menotropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2017-02-02 |
| Phase | Phase 4 |
What the finished NCT02554279 record still lists
NCT02554279 is an interventional study that assigns participants to a tested intervention. The registered 620 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which recombinant FSH is the first listed.
NCT02554279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02554279 about?
NCT02554279 is a clinical study titled "MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population". The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation (COS) following GnRH treatment.
What is the current status of trial NCT02554279?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 620 participants. The study started on 2015-08-31. Estimated completion is 2017-02-02.
What interventions are being tested in trial NCT02554279?
The interventions under investigation include: recombinant FSH (DRUG), menotropin (DRUG).
Who is sponsoring clinical trial NCT02554279?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02554279's enrollment target sits among peer trials
620 131st of 2000 higher than 1,870 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI